These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7889690)

  • 21. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
    Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
    Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique.
    Browne TR; Szabo GK; McEntegart C; Evans JE; Evans BA; Miceli JJ; Quon C; Dougherty CL; Kres J; Davoudi H
    J Clin Pharmacol; 1993 Jan; 33(1):89-94. PubMed ID: 8429121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new method for simultaneous quantification of fosphenytoin, phenytoin and its primary metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin in whole blood by ultra-performance liquid chromatography-tandem mass spectrometry.
    Suzuki T; Ogawa T; Ueyama J; Iwai M; Kondo F; Seno H
    Leg Med (Tokyo); 2018 Sep; 34():64-69. PubMed ID: 30195106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.
    Krueger KA; Garnett WR; Comstock TJ; Fitzsimmons WE; Karnes HT; Pellock JM
    Epilepsia; 1987; 28(6):706-12. PubMed ID: 3121288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.
    Factor SA; Weiner WJ; Hefti F
    Ann Neurol; 1989 Aug; 26(2):286-8. PubMed ID: 2774516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible mechanisms for the pharmacokinetic interaction between phenytoin and folinate in rats.
    Yamasaki D; Tsujimoto M; Ohdo S; Ohtani H; Sawada Y
    Ther Drug Monit; 2007 Aug; 29(4):404-11. PubMed ID: 17667793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible function of astrocyte cytochrome P450 in control of xenobiotic phenytoin in the brain: in vitro studies on murine astrocyte primary cultures.
    Meyer RP; Knoth R; Schiltz E; Volk B
    Exp Neurol; 2001 Feb; 167(2):376-84. PubMed ID: 11161626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.
    Antunes Viegas D; Rodrigues M; Francisco J; Falcão A; Alves G; Santos AO
    Eur J Pharm Sci; 2016 Jun; 89():61-72. PubMed ID: 27106504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic interactions of phenytoin in the rat: effect of coadministration with the anticonvulsant drugs sodium valproate, sulthiame, ethosuximide or phenobarbital.
    Patsalos PN; Lascelles PT
    Gen Pharmacol; 1984; 15(1):7-12. PubMed ID: 6141984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.
    Walton NY; Uthman BM; El Yafi K; Kim JM; Treiman DM
    Epilepsia; 1999 Feb; 40(2):153-6. PubMed ID: 9952260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of phenytoin in perfused human placenta.
    Shah YG; Miller RK
    Pediatr Pharmacol (New York); 1985; 5(3):165-79. PubMed ID: 4094813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta.
    Dickinson RG; Fowler DW; Kluck RM
    Clin Exp Pharmacol Physiol; 1989 Oct; 16(10):789-97. PubMed ID: 2612061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver enzyme abnormalities in Parkinson's disease.
    Tanner CM
    Geriatrics; 1991 Aug; 46 Suppl 1():60-3. PubMed ID: 1894148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man.
    Witkin KM; Bius DL; Teague BL; Wiese LS; Boyles LW; Dudley KH
    Ther Drug Monit; 1979; 1(1):11-34. PubMed ID: 553326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.
    Tanner CM
    Neurology; 1991 May; 41(5 Suppl 2):89-91; discussion 92. PubMed ID: 2041601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation.
    Randinitis EJ; Buchanan RA; Kinkel AW
    Epilepsia; 1990; 31(4):458-64. PubMed ID: 2369880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenytoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin do not alter the effects of bacterial and amplified plaque extracts on cultures of fibroblasts from normal and overgrown gingivae.
    Smith QT; Hinrichs JE
    J Dent Res; 1987 Aug; 66(8):1393-8. PubMed ID: 3476609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.